The Phase 1 study (NCT04674306), conducted at Cleveland Clinics Main Campus in partnership with Anixa Biosciences, Inc., included 35 patients across three cohorts: Launched in 2021, the trial enrolled 26 patients in Phase 1a, four in Phase 1b, and five in Phase 1c
This antioxidant reinforcement, applied topically and consistently, helps preserve the integrity of follicular stem cells and the ECM, slowing the cellular aging of the scalp in ways that directly translate to sustained, healthy hair growth over time
GGsTop activity remained stable in water at room temperature (Extended Data Fig
Not for human use.) Synergistic GH release observed in human and rodent research models when peptides are combined, as noted in published preclinical studies Sustained IGF-1 signaling observed in preclinical models following CJC-1295 administration, with additional pulsatile activity from Ipamorelin Minimal cortisol, prolactin, or ACTH perturbation observed in preclinical secretagogue studies supporting a selective GH signaling profile Studied in preclinical models in the context of body composition, bone density, lipid oxidation, and sleep physiology research Investigated in the context of tissue repair, immune signaling, and collagen synthesis in laboratory settings Referenced in research contexts involving sarcopenia, cachexia, and recovery biology Why Researchers Choose This CJC-1295 + Ipamorelin Blend Widely referenced GH-axis research blend Exact sequence match with literature-referenced structures Transparent analytical data: HPLC 98%, MS confirmation Used in endocrinology and physiology laboratory research settings Competitive pricing with bulk options For Research Use Only
FEBS J 276(22):64746482
10.1152/ajpendo.1997.273.5.E981 82
